{"id":40111,"date":"2025-08-26T15:21:19","date_gmt":"2025-08-26T07:21:19","guid":{"rendered":"https:\/\/flcube.com\/?p=40111"},"modified":"2025-08-26T15:21:20","modified_gmt":"2025-08-26T07:21:20","slug":"anke-biotech-secures-long%e2%80%91acting-fsh%e2%80%91ctp-approval-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40111","title":{"rendered":"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China"},"content":{"rendered":"\n<p>Shanghai Bao\u202fPharmaceuticals Co.,\u202fLtd. has received official marketing authorization from China\u2019s National Medical Products Administration (NMPA) for its recombinant human follicle\u2011stimulating hormone\u2011CTP fusion protein. The product, the country\u2019s first long\u2011acting recombinant FSH\u2011CTP, will be distributed exclusively by Anhui Anke Biotechnology (Group) Co.,\u202fLtd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/300009:SHE\">SHE: 300009<\/a>) under a July\u202f2025 agreement that covers mainland China, Hong\u202fKong, Macau, and Taiwan.<\/p>\n\n\n\n<p><strong>Product Overview<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Name:<\/strong> Recombinant human FSH\u2011CTP fusion protein<\/li>\n\n\n\n<li><strong>Structure:<\/strong> Amino\u2011acid sequence identical to EU\u2011approved Corifollitropin\u202f\u03b1 (CFA)<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Single\u2011dose injection<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Controlled ovarian stimulation (COS) in combination with GnRH antagonists<\/li>\n\n\n\n<li><strong>Benefits:<\/strong> Comparable oocyte yield, embryo quality, and pregnancy outcomes to short\u2011acting FSH; enhanced safety profile; reduced dosing frequency<\/li>\n<\/ul>\n\n\n\n<p><strong>Regulatory Milestone<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approval Date:<\/strong> 30\u202fJune\u202f2025 (NMPA)<\/li>\n\n\n\n<li><strong>Significance:<\/strong> First long\u2011acting recombinant FSH\u2011CTP approved in China, opening a new class of fertility therapeutics in the domestic market<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Efficacy &amp; Patient Impact<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Comparable Outcomes:<\/strong> Clinical trials demonstrate parity with conventional short\u2011acting FSH for key metrics (retrieved oocytes, embryo quality, live\u2011birth rates).<\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> Lower incidence of ovarian hyperstimulation syndrome (OHSS) reported in the pivotal study.<\/li>\n\n\n\n<li><strong>Convenience:<\/strong> Single\u2011dose regimen cuts the number of clinic visits by ~70\u202f%, improving patient adherence and reducing overall treatment burden.<\/li>\n<\/ul>\n\n\n\n<p><strong>Distribution Agreement &amp; Market Outlook<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Rights:<\/strong> Anke Biotech holds sole distribution rights across all Chinese territories, positioning it as the primary market entrant for long\u2011acting FSH therapy.<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Target high\u2011volume fertility centers and IVF clinics; leverage existing sales network to accelerate uptake.<\/li>\n\n\n\n<li><strong>Growth Projection:<\/strong> Analyst estimates a 30\u201140\u202f% market share of the domestic long\u2011acting FSH segment within 3\u202fyears, translating to an incremental revenue run\u2011rate of USD\u202f20\u201130\u202fmillion by 2028.<\/li>\n<\/ul>\n\n\n\n<p><strong>Company Statements<\/strong><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThe NMPA approval validates our commitment to delivering innovative, patient\u2011centric fertility solutions,\u201d said <strong>Ms. Li<\/strong>, Chief Commercial Officer at Anke Biotech. \u201cOur exclusive partnership with Shanghai\u202fBao enables us to bring this breakthrough therapy to Chinese patients faster and more safely.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p><strong>Bottom Line<\/strong><br>The NMPA green light for Shanghai\u202fBao\u2019s FSH\u2011CTP, coupled with Anke Biotech\u2019s exclusive distribution rights, marks a pivotal moment for China\u2019s reproductive medicine market. The single\u2011dose, long\u2011acting formulation promises to streamline ovarian stimulation protocols, enhance safety, and deliver significant value to patients and clinicians alike.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Bao\u202fPharmaceuticals Co.,\u202fLtd. has received official marketing authorization from China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40113,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[482,3258,15,997],"class_list":["post-40111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-anke-biotechnology","tag-bao-pharmaceuticals","tag-product-approvals","tag-she-300009"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Bao\u202fPharmaceuticals Co.,\u202fLtd. has received official marketing authorization from China\u2019s National Medical Products Administration (NMPA) for its recombinant human follicle\u2011stimulating hormone\u2011CTP fusion protein. The product, the country\u2019s first long\u2011acting recombinant FSH\u2011CTP, will be distributed exclusively by Anhui Anke Biotechnology (Group) Co.,\u202fLtd. (SHE: 300009) under a July\u202f2025 agreement that covers mainland China, Hong\u202fKong, Macau, and Taiwan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40111\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China\" \/>\n<meta property=\"og:description\" content=\"Shanghai Bao\u202fPharmaceuticals Co.,\u202fLtd. has received official marketing authorization from China\u2019s National Medical Products Administration (NMPA) for its recombinant human follicle\u2011stimulating hormone\u2011CTP fusion protein. The product, the country\u2019s first long\u2011acting recombinant FSH\u2011CTP, will be distributed exclusively by Anhui Anke Biotechnology (Group) Co.,\u202fLtd. (SHE: 300009) under a July\u202f2025 agreement that covers mainland China, Hong\u202fKong, Macau, and Taiwan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40111\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T07:21:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T07:21:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2613.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China\",\"datePublished\":\"2025-08-26T07:21:19+00:00\",\"dateModified\":\"2025-08-26T07:21:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111\"},\"wordCount\":386,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2613.webp\",\"keywords\":[\"Anke Biotechnology\",\"Bao Pharmaceuticals\",\"Product approvals\",\"SHE: 300009\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40111#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40111\",\"name\":\"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2613.webp\",\"datePublished\":\"2025-08-26T07:21:19+00:00\",\"dateModified\":\"2025-08-26T07:21:20+00:00\",\"description\":\"Shanghai Bao\u202fPharmaceuticals Co.,\u202fLtd. has received official marketing authorization from China\u2019s National Medical Products Administration (NMPA) for its recombinant human follicle\u2011stimulating hormone\u2011CTP fusion protein. The product, the country\u2019s first long\u2011acting recombinant FSH\u2011CTP, will be distributed exclusively by Anhui Anke Biotechnology (Group) Co.,\u202fLtd. (SHE: 300009) under a July\u202f2025 agreement that covers mainland China, Hong\u202fKong, Macau, and Taiwan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40111\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2613.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2613.webp\",\"width\":1080,\"height\":608,\"caption\":\"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40111#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Bao\u202fPharmaceuticals Co.,\u202fLtd. has received official marketing authorization from China\u2019s National Medical Products Administration (NMPA) for its recombinant human follicle\u2011stimulating hormone\u2011CTP fusion protein. The product, the country\u2019s first long\u2011acting recombinant FSH\u2011CTP, will be distributed exclusively by Anhui Anke Biotechnology (Group) Co.,\u202fLtd. (SHE: 300009) under a July\u202f2025 agreement that covers mainland China, Hong\u202fKong, Macau, and Taiwan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40111","og_locale":"en_US","og_type":"article","og_title":"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China","og_description":"Shanghai Bao\u202fPharmaceuticals Co.,\u202fLtd. has received official marketing authorization from China\u2019s National Medical Products Administration (NMPA) for its recombinant human follicle\u2011stimulating hormone\u2011CTP fusion protein. The product, the country\u2019s first long\u2011acting recombinant FSH\u2011CTP, will be distributed exclusively by Anhui Anke Biotechnology (Group) Co.,\u202fLtd. (SHE: 300009) under a July\u202f2025 agreement that covers mainland China, Hong\u202fKong, Macau, and Taiwan.","og_url":"https:\/\/flcube.com\/?p=40111","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T07:21:19+00:00","article_modified_time":"2025-08-26T07:21:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2613.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40111#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40111"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China","datePublished":"2025-08-26T07:21:19+00:00","dateModified":"2025-08-26T07:21:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40111"},"wordCount":386,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40111#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2613.webp","keywords":["Anke Biotechnology","Bao Pharmaceuticals","Product approvals","SHE: 300009"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40111#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40111","url":"https:\/\/flcube.com\/?p=40111","name":"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40111#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40111#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2613.webp","datePublished":"2025-08-26T07:21:19+00:00","dateModified":"2025-08-26T07:21:20+00:00","description":"Shanghai Bao\u202fPharmaceuticals Co.,\u202fLtd. has received official marketing authorization from China\u2019s National Medical Products Administration (NMPA) for its recombinant human follicle\u2011stimulating hormone\u2011CTP fusion protein. The product, the country\u2019s first long\u2011acting recombinant FSH\u2011CTP, will be distributed exclusively by Anhui Anke Biotechnology (Group) Co.,\u202fLtd. (SHE: 300009) under a July\u202f2025 agreement that covers mainland China, Hong\u202fKong, Macau, and Taiwan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40111#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40111"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40111#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2613.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2613.webp","width":1080,"height":608,"caption":"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40111#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Anke Biotech Secures Long\u2011Acting FSH\u2011CTP Approval in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2613.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40111"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40111\/revisions"}],"predecessor-version":[{"id":40114,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40111\/revisions\/40114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40113"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}